Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | MPL | P40238 | 3/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.38 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.38 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4443159 | 0.83 | KIF11 (0.43) | AAK1KIF11MPLPIK3CD | |
| SCHEMBL29403371 | 0.82 | KIF11 (0.50) | KIF11MPLPIK3CD | |
| SCHEMBL349356 | 0.82 | KIF11 (0.50) | KIF11MPLPIK3CD | |
| SCHEMBL2924757 | 0.81 | KIF11 (0.53) | AAK1S1PR1KIF11MPLPIK3CD | |
| SCHEMBL5105685 | 0.80 | PIK3CD (0.49) | KIF11MPLPIK3CD | |
| Hydrochloric Acid SCHEMBL8644024 | 0.80 | KIF11 (0.48) | KIF11MPLPIK3CD | |
| Hydrochloric Acid SCHEMBL4439149 | 0.79 | KIF11 (0.52) | AAK1S1PR1KIF11MPLPIK3CD | |
| SCHEMBL4447731 | 0.77 | AAK1 (0.46) | AAK1S1PR1MAP4K4 | |
| SCHEMBL24197382 | 0.76 | PIK3CD (0.41) | S1PR1KIF11MPLPIK3CDNOS3 | |
| SCHEMBL22068158 | 0.75 | IDO1 (0.55) | S1PR1ADORA2BMAP4K4MINK1TNIK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080167348-A1 | NOVEL SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-10 | — | — | US | claimed |
| EP-2118062-A1 | SULFONAMIDE DERIVATIVES AS CHYMASE INHIBITORS | F. Hoffmann-Roche AG (CH) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008084004-A1 | SULFONAMIDE DERIVATIVES AS CHYMASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-17 | — | — | WO | disclosed |
| US-20080167348-A1 | NOVEL SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167348-A1 | NOVEL SULFONAMIDE DERIVATIVES | CMA1, ARSA, TPSAB1 | AAK1 3703/4885S1PR1 1218/4885KIF11 4436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.